Philip O. Buck

Impact of PD-1 and PD-L1 inhibitors on patient-reported outcomes in esophageal squamous cell carcinoma: a systematic review of clinical trials

OBJECTIVES: Esophageal squamous cell carcinoma (ESCC) carries a poor prognosis and is associated with symptoms such as dysphagia that substantially impair patients' health-related quality of life (HRQoL). The combination of chemotherapy with an immune checkpoint inhibitor is wide...